Prior Lines of Therapy — The Detail That Changes Everything

There are a few phrases in clinical research that look simple on paper but are anything but simple in practice.

“Prior lines of therapy” is one of them.

It shows up in every oncology protocol and is often included in the inclusion criteria. It can be specified as ≤2 prior lines, ≥1 prior line, exactly 1 prior line, no prior exposure to X, no prior exposure to a drug in the same class, relapse after Y, or refractory to Z.

These phrases seem clean, structured, and seemingly straightforward until you actually try to apply them. 

As a medical monitor, I’ve learned that prior lines of therapy are rarely just a checkbox. They are a clinical story, and if we don’t read that story carefully, we risk misclassifying patients, misinterpreting safety, and sometimes even misjudging efficacy.

Let’s unpack why this matters more than we tend to admit.

A Line of Therapy Is Not a Line on a Page

In the real world, a “line” isn’t always cleanly defined. Patients don’t progress on cue, and they don’t neatly stop one regimen and start another with textbook documentation.

So, what counts as a new line? Is dose escalation within the same regimen considered a new line? Is adding a targeted agent to backbone therapy a new line? Is maintenance therapy its own line? What about re-treatment with the same regimen after a long remission? Does transplant reset the count?

The protocol may define it, but definitions vary across sponsors, across indications, and sometimes across studies within the same development program.

From a monitoring standpoint, ambiguity is not academic; it directly impacts eligibility. If a study requires “1–2 prior lines,” and a patient has technically had three by one interpretation and two by another, you have a decision point. That decision can affect safety exposure, data integrity, and ultimately regulatory positioning.

This is where medical monitoring stops being administrative and becomes clinical. You need to understand the disease course, the intent of therapy, and whether a modification was truly a new line or a continuation of an existing one. And sometimes, you may even need to push back.

Why Sponsors Care So Much About Prior Lines

There’s a reason this variable is closely monitored. Prior lines of therapy serve as a proxy for disease biology and treatment resistance. The more prior lines a patient has received, the more refractory the disease tends to be. They also carry more cumulative toxicity, potentially compromising organ reserve. Consequently, the safety signal becomes more complex. 

Enrolling heavily pretreated patients into an early-phase study doesn’t evaluate a drug in isolation. Instead, it assesses it in the context of marrow exhaustion, hepatic stress, neuropathy, cytopenias, cardiotoxicity, and sometimes immune dysregulation resulting from prior therapies.

When adverse events arise, interpretation becomes multifactorial:

• Is this the investigational drug?

• Is this cumulative toxicity?

• Is this disease progression?

• Is this residual damage from prior treatment?

Prior therapy history becomes crucial to causality assessment. It also shapes efficacy expectations. A 20% response rate in a 5th-line setting is different from 20% in 1st-line relapse. Regulators, investigators, investors, and patients all recognize this. Context is everything.

The Hidden Risk: Class Exposure

Another layer that complicates the picture is prior exposure to drugs within the same mechanism class.

Take targeted therapies for example. If a patient previously received a drug targeting the same pathway, are they truly “naïve” to the mechanism? Or are we enrolling a pre-resistant population?

This question becomes particularly important when developing next-generation inhibitors, designing combination regimens, or even interpreting durability of response.

From a safety standpoint, prior class exposure also matters. Some toxicities are class effects, while others are molecule-specific. Without clarity on prior exposure, it becomes challenging to attribute safety signals accurately. 

In my experience, this is one of the most underappreciated sources of protocol deviation. While sites may document prior chemotherapy accurately, targeted agents and short-lived regimens sometimes slip through eligibility discussions unless actively reviewed. Which is why eligibility review calls matter. They are not a formality, but rather are a risk mitigation measure.

Lines of Therapy and the Ethics of Trial Design

There’s also an ethical aspect to consider here.

When we restrict trials to patients with multiple prior lines, we are often entering the space of limited options. That can be justified because it protects earlier-line standards of care and allows safety to be established in more refractory populations. However, it also means that patients enrolling in such trials may have lower performance status, higher symptom burden, or greater vulnerability.

We need to be transparent about these factors when designing studies and when interpreting outcomes. Phase I trials, for example, frequently enroll patients who have exhausted standard therapy. This reality influences the safety landscape and how we communicate risk.

Prior lines of therapy are not just a statistical variable. They reflect how far along someone is in their disease journey and this deserves our attention.

Operational Realities: Where Things Go Wrong

From a monitoring perspective, here’s where prior line classification often encounters challenges: 

• Incomplete documentation - Outside records may be missing details such as start and stop dates, intent, or reason for discontinuation.

• Ambiguous progression timing - It’s crucial to determine whether progression occurred during therapy (refractory) or after its completion (relapsed). This distinction can significantly impact stratification.

• Bridging therapy confusion - Short courses used as disease control while awaiting transplant or study enrollment are sometimes miscounted.

• Maintenance therapy misclassification - Some protocols treat maintenance as a continuation of the same line, while others count it separately.

• Re-challenge scenarios - Retreatment after a prolonged remission may or may not be considered a new line, depending on the protocol.

If these issues are not addressed early, they can lead to downstream problems, including eligibility queries, database corrections, and sometimes difficult conversations about screen failures.

Proactive medical oversight is essential to prevent these issues. It is far easier to clarify the situation before enrollment than to address it after.

Prior Lines and Data Interpretation

When I review safety listings or emerging efficacy data, one of the first filters I look at is the number of prior lines. 

Patterns emerge quickly, such as higher-grade cytopenias tend to cluster in heavily pretreated patients, while lower response durability is observed in those who have experienced multiple refractory regimens. Additionally, unexpected toxicities are more prevalent in patients with prior immunotherapy exposure. Without stratifying data based on prior therapy burden, it can be misleading. 

In discussions about development strategies, prior lines also play a crucial role in determining positioning. For instance, it helps to decide whether a drug is intended as a salvage therapy or if it aims to advance earlier in the treatment course.

Furthermore, it is essential to assess the competitive landscape at each line of treatment and consider how regulators will evaluate the benefit-risk profile in that setting. 

It is important to recognize that a drug that may be acceptable in the 4th line of treatment may not meet the threshold for approval in the 1st line. This is because the tolerance for toxicity can shift as the expected benefit of the treatment increases. Therefore, understanding prior therapy exposure is a fundamental aspect of this equation. 

The Human Layer

It’s easy to discuss lines of therapy clinically, but behind every “third-line patient” is a person who has already endured surgery, infusions, hospitalizations, side effects, and uncertainty.

When I encounter “≥3 prior lines” in a protocol, I don’t just think about resistance patterns; I think about the cumulative experience of the patient. 

As medical monitors, we sit at the intersection of protocol design, patient safety, and data integrity. While we may not interact with every patient directly, our decisions significantly influence who receives access to a trial and how their data is interpreted.

That responsibility goes beyond simply counting regimens; it demands clinical judgment.

Final Thoughts

Prior lines of therapy, often presented as a simple eligibility variable, hold significant influence over various aspects of clinical trials. They determine who is eligible to participate, shape the interpretation of safety data, contextualize the efficacy of treatments, impact regulators’ assessments of benefit-risk, and strategically position development programs. 

Misclassification of prior lines of therapy, if done carelessly, introduces bias and risk, while thoughtful classification strengthens the integrity of the entire program.

Therefore, the next time you see “1–2 prior lines” in a protocol, pause and ask what it really means in the specific disease context. Ask how it will be operationalized and its implications for safety interpretation.

In oncology development, a line of therapy is never just a chronological marker; instead, it carries historical significance, biological relevance, strategic importance, and sometimes even the distinction between a clean dataset and a compromised one.